September 25, 2024CancersOpen Access

Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis

View Full Paper

Ask AI

Bookmark

Overall survival improved significantly in myelofibrosis following allogeneic hematopoietic stem-cell transplantation during recent years, driven by lower non-relapse mortality.
Median overall survival reached 48.9 months in the earlier group but was not reached recently, while non-relapse mortality dropped significantly.
Retrospective, single-center study evaluated 36 adults across two eras, highlighting ruxolitinib and intensified conditioning as primary drivers of benefit.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective study demonstrates improved survival in adult patients with myelofibrosis, highlighting the benefits of ruxolitinib pretreatment and intensified conditioning.

Cite This Study

Machherndl‐Spandl et al. (2024) studied this question.

synapsesocial.com/papers/68e57665b6db643587516476 https://doi.org/10.3390/cancers16193257

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study demonstrates improved survival in adult patients with myelofibrosis, highlighting the benefits of ruxolitinib pretreatment and intensified conditioning.

Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis

Key Points

Discussion

Implication

Cite This Study

Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider